biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
3B5, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
human, mouse
manufacturer/tradename
Calbiochem®
storage condition
do not freeze
dilution
(Frozen Sections (2.5 µg/mL)
Immunoblotting (2-3 µg/mL,
Immunofluorescence (2.5 µg/mL)
Immunoprecipitation (1 µg/sample,
Paraffin Sections (2.5 µg/mL, pressure cooker, heat or trypsin pre-treatment required, )
isotype
IgG1
shipped in
wet ice
storage temp.
2-8°C
target post-translational modification
unmodified
Gene Information
human ... ERBB2(2064)
General description
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with Sp2/0.Ag14 cells (see application references). Recognizes the ~185 kDa c-Erb2/c-Neu protein.
Recognizes the ~185 kDa c-ErbB2/c-Neu protein in HEK293 cells.
Anti-c-ErbB2/c-Neu (Ab-3), mouse monoclonal, clone 3B5, recognizes the ~185 kDa c-ErbB2/c-Neu protein in HEK293 cells. It is validated for WB, IF, IP, and IHC on frozen and paraffin sections.
Immunogen
Human
a synthetic peptide (TAENPEYLGLDVPV) corresponding to amino acids 1242-1255 from the C-terminal domain of human c-ErbB2/c-Neu
Application

Frozen Sections (2.5 g/ml)
Immunoblotting (2-3 g/ml, see application references)
Immunofluorescence (2.5 g/ml)
Immunoprecipitation (1 g/sample, see application references)
Paraffin Sections (2.5 g/ml, pressure cooker, heat or trypsin pre-treatment required, see application references)
Packaging
Please refer to vial label for lot-specific concentration.
Physical form
In 0.05 M sodium phosphate buffer, 0.2% gelatin.
Analysis Note
Negative Control
HepG2 cells or normal skin
HepG2 cells or normal skin
Positive Control
SK-BR-3 cells or breast carcinoma tissue
SK-BR-3 cells or breast carcinoma tissue
Other Notes
For paraffin sections, we recommend pre-treating with a pressure cooker, but trypsin and heat will also work well. Including 0.05% saponin during staining of paraffin sections may help reduce background. In one study ductal carcinomas in situ displaying large-cell, comedo growth type, were stained while none of 16 ductal carcinomas in situ of small-cell, papillary, or cribriform growth type were stained by this antibody. Antibody should be titrated for optimal results in individual systems.
Mamcs, J.R., et al. 1994. Ann. Surg.219, 332.
Tetu, B., et al. 1994. Cancer73, 2359.
DiFiore, P.P., et al. 1987. Science237, 178.
Slamon, D.J., et al. 1987. Science235, 177.
Varley, J.M., et al. 1987. Oncogene1, 423.
Bargmann, C.I., et al. 1986. Nature319, 226.
Yamamoto, T., et al. 1986. Nature319, 230.
Blick, M., et al. 1984. Blood64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory 2, 215.
Tetu, B., et al. 1994. Cancer73, 2359.
DiFiore, P.P., et al. 1987. Science237, 178.
Slamon, D.J., et al. 1987. Science235, 177.
Varley, J.M., et al. 1987. Oncogene1, 423.
Bargmann, C.I., et al. 1986. Nature319, 226.
Yamamoto, T., et al. 1986. Nature319, 230.
Blick, M., et al. 1984. Blood64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory 2, 215.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
存储类别
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Henriette O'Geen et al.
Epigenetics & chromatin, 12(1), 26-26 (2019-05-06)
Rewriting of the epigenome has risen as a promising alternative to gene editing for precision medicine. In nature, epigenetic silencing can result in complete attenuation of target gene expression over multiple mitotic divisions. However, persistent repression has been difficult to
Peter Nagy et al.
Journal of cell science, 115(Pt 22), 4251-4262 (2002-10-12)
The ErbB family of transmembrane receptor tyrosine kinases plays an important role in the pathogenesis of many cancers. The four members of the family, ErbB1-4, form various homo- and heterodimers during the course of signal transduction. A second hierarchical level
Zongming Liu et al.
Scientific reports, 9(1), 622-622 (2019-01-27)
Breast cancer brain metastasis (BCBM) remains a major clinical problem. Approximately 10-16% of patients with breast cancer develop brain metastases (BCBM). However, no systemic therapy has gained regulatory approval for the specific treatment of BCBM and this remains an area
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| OP15-100UG | 04055977224658 |